HomeAI · summaries
Storia in 2 fonti
Jazz zeroes in on next-gen T cell engagers with AbCellera deal
The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited success outside of certain blood cancers.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Jazz zeroes in on next-gen T cell engagers with AbCellera deal
The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited success outside of…
- ·
benzinga.com
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration - AbCellera Biologics (NASD
Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets despite a recent Zepzelca trial setback.